SCHEMBL5170335

SCHEMBL5170335

C=C(c1ccccc1)c1cc(C)ccc1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.48
GAA P10253 1/20 0.48
ACHE P22303 1/20 0.47
NPC1 O15118 3/20 0.46
RAB9A P51151 2/20 0.46
SRC P12931 2/20 0.44
TGFBR1 P36897 2/20 0.44
MAPT P10636 3/20 0.43
ALDH1A1 P00352 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CYP3A4 P08684 1/20 0.43
RXRA P19793 1/20 0.43
KCNK3 O14649 1/20 0.42
KCNK9 Q9NPC2 1/20 0.42
EPHX1 P07099 1/20 0.42
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4319151 0.85 MAPT (0.54) TP53NPC1RAB9AMAPTALDH1A1
SCHEMBL30070877 0.85 ABCB1 (0.40) TP53GAASRCTGFBR1MAPT
SCHEMBL28558451 0.82 RAB9A (0.54) TP53NPC1RAB9AMAPTALDH1A1
SCHEMBL5171849 0.82 MRGPRX4 (0.52) NPC1RAB9AMAPTALDH1A1KMT2A
SCHEMBL16105803 0.80 NPSR1 (0.45) MEN1KMT2AHTTCYP3A4RXRA
SCHEMBL30785077 0.79 TP53 (0.66) TP53GAASRCTGFBR1MAPT
SCHEMBL3964231 0.79 TP53 (0.66) TP53GAASRCTGFBR1MAPT
SCHEMBL5171059 0.79 CSNK2A1 (0.53) TP53GAANPC1RAB9AMAPT
SCHEMBL29726796 0.77 MAPT (0.49) TP53GAANPC1MAPTALDH1A1
SCHEMBL6546292 0.77 NFE2L2 (0.46) TP53NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1299342-B1 METHOD FOR PRODUCING 3,3-DIARYLPROPYLAMINES SANOL ARZNEI SCHWARZ GMBH (DE) 2007-05-02 EP disclosed
EP-1299342-B1 METHOD FOR PRODUCING 3,3-DIARYLPROPYLAMINES SANOL ARZNEI SCHWARZ GMBH (DE) 2007-05-02 EP disclosed
US-6809225-B2 BY HYDROCARBONYLATION/HYDROFORMYLATION WITH SUBSEQUENT REDUCTIVE AMINATION SCHWARZ PHARMA AG (DE) 2004-10-26 US disclosed
US-20040034080-A1 Method for producing 3,3-diarylpropylamines UCB PHARMA GMBH (DE) 2004-02-19 US disclosed
EP-1299342-A1 METHOD FOR PRODUCING 3,3-DIARYLPROPYLAMINES SCHWARZ PHARMA AG (DE) 2003-04-09 EP disclosed
WO-2002004399-A1 METHOD FOR PRODUCING 3,3-DIARYLPROPYLAMINES SCHWARZ PHARMA AG (DE) 2002-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034080-A1 Method for producing 3,3-diarylpropylamines HNMT, CYP1A1, HRH3 TP53 3909/4885GAA 3558/4885ACHE 4016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.